fbpx
Medical Innovation Exchange

Atara's stock plummets 38% afterhours following mystifying phase 2 data review

https://www.fiercebiotech.com/biotech/atara-stock-plummets-3x-afterhours-following-mystifying-phase-2-data-review

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.